CAR-T for Pediatric B-ALL: Expert Tips

In this episode, Prof André Baruchel discusses the role of CAR T-cell therapy in children with B-cell acute lymphoblastic leukemia (B-ALL). He reviews current indications for CAR T-cell treatment, including relapsed and refractory disease, and explores whether CAR T could move earlier in the treatment pathway. The discussion also examines how CAR T-cell therapy compares with transplantation, blinatumomab, and other salvage strategies, as well as the factors that influence long-term outcomes and relapse risk.   The conversation highlights key questions surrounding the role of allo-HSCT in the CAR T era. Prof Baruchel also explores emerging approaches designed to improve outcomes, including dual-targeted CARs, strategies to enhance cellular persistence. Listen now for insights into how fourth-generation CAR constructs that modify the tumour microenvironment, and *in vivo* CAR therapies may further transform the treatment of pediatric B-ALL. Guests:  Prof André Baruchel  Affiliation: Professor of Pediatrics, Université Paris-Cité; former Head of the Pediatric Hematology Immunology Department, Hôpital Robert-Debré, Paris Host: Leah DeLeon  **Learn More** What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA\_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠